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SUMMARY 
Bladder cancer incurs a higher lifetime treatment cost than other cancers due to frequent 
recurrence of non-invasive disease. Improved prognostic biomarkers and localised therapy 
are needed for this large patient group. We defined two major genomic subtypes of primary 
stage Ta tumors that showed differential risk of recurrence. The higher risk subtype was 
characterised by loss of 9q including TSC1, increased KI67 labelling index, upregulated 
glycolysis, DNA repair, mTORC1 signaling, features of the unfolded protein response and 
altered cholesterol homeostasis. Comparison with muscle-invasive bladder cancer mutation 
profiles revealed lower overall mutation rates and more frequent mutations in RHOB and 
chromatin modifier genes. More mutations in the histone-lysine demethylase KDM6A were 
present in non-invasive tumors from females than males. 
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SIGNIFICANCE 
Non-invasive (stage Ta) bladder tumors are the largest group of bladder tumors and 
although there is heterogeneity in outcome, these are currently treated similarly. We 
identified two major genomic subtypes, one of which is associated with distinct DNA copy 
number and gene mutation profile and expression changes that appear related to loss of 
expression of one or both copies of TSC1. This identifies a metabolic vulnerability with 
potential for therapeutic intervention in >50 % of cases. We also identified a gender-related 
molecular difference. The high frequency of mutation of the histone demethylase KDM6A in 
female tumors may indicate a distinct epigenetic landscape in the female bladder.  
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INTRODUCTION 
The majority of bladder tumors are non-muscle-invasive bladder cancers (NMIBC). Of the 
estimated 429,000 new cases of bladder cancer diagnosed each year worldwide (Ferlay et 
al., 2015), approximately 75% are NMIBC (Babjuk et al., 2017). NMIBC include high-grade 
tumors that invade the submucosa (stage T1) and carcinoma in situ (CIS), which have high 
risk of progression to muscle invasion and may require cystectomy. However, the largest 
group of NMIBC are non-invasive bladder cancers (NIBC) that do not penetrate the epithelial 
basement membrane (stage Ta). The recommended treatment for low risk Ta tumors is 
resection followed by a single instillation of a chemotherapy agent, and for intermediate risk 
tumors, induction and maintenance intravesical chemotherapy or BCG (Babjuk et al., 2017). 
Patients with NIBC have long life-expectancy. However local disease recurrence in 
up to 70% of cases necessitates long-term disease monitoring via cystoscopy. 
Consequently, bladder cancer has high prevalence (Ploeg et al., 2009) and incurs a higher 
lifetime cost for treatment than all other cancers (James and Gore, 2013; Svatek et al., 
2014). Assessment of risk of recurrence and progression and associated treatment 
decisions are based on a nomogram that includes tumor size, grade, multifocality and the 
presence of CIS (Sylvester et al., 2006). This stratification is not yet complemented by 
molecular biomarkers and no biomarker-guided localised treatments have been developed. 
Recent studies have used gene expression analysis to sub-classify bladder tumors 
and seek prognostic signatures. In muscle-invasive bladder cancer (MIBC), expression 
subgroups show relationships to outcome and therapeutic response (Choi et al., 2014; 
Damrauer et al., 2014; Cancer Genome Atlas Research Network, 2014a). Less information 
is available for NMIBC. However, a study that included both NMIBC and MIBC showed 
segregation of NMIBC across several expression subgroups (Sjodahl et al., 2012) and 
recently a large study of the entire spectrum of NMIBC confirmed this molecular 
heterogeneity and defined three expression classes with prognostic implications (Hedegaard 
et al., 2016).   
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Although there has been extensive analysis of the genome of MIBC (Gui et al., 2011; 
Guo et al., 2013; Nellist et al., 1999; Cancer Genome Atlas Research Network, 2014a), only 
small numbers of stage Ta NIBC have been analysed by genome sequencing (Balbas-
Martinez et al., 2013; Nordentoft et al., 2014). Common features identified by candidate 
gene analysis include mutations in the TERT promoter, activating point mutations in FGFR3 
and PIK3CA, and inactivating mutations in STAG2 (Reviewed in (Knowles and Hurst, 
2015)). Our previous genome-wide copy number analysis revealed two major genomic sub-
groups of stage Ta tumors (Hurst et al., 2012). However, knowledge of their mutational 
landscape remains incomplete and definition of subtypes based on mutational signatures 
has not been attempted. Identification of biomarkers for increased risk of recurrence may 
allow modification of disease monitoring and improved biological understanding may 
suggest approaches to localised therapy for these patients. Here we investigate the 
relationships of genomic copy number profile, expression subtype membership and mutation 
signature with patient gender and outcome in NIBC. 
 
RESULTS 
We analysed 140 primary stage Ta transitional cell carcinomas and matched blood. These 
were selected based on initial diagnostic assessment as grade 1 or 2 according to the 1973 
WHO classification (WHO, 1973). All were re-evaluated for this study by a single pathologist 
(J-A R). Clinicopathologic data including 1973 and 2004 WHO classifications (Eble et al., 
2004; WHO, 1973) are summarised in Table S1. The majority (134/140) were grade 1/2 
according to the 1973 classification system; 61% were low and 39% high grade according to 
the 2004 system. Median age at diagnosis was 71, and the male:female ratio was 2.06. We 
also analysed a recently-established grade 2 stage Ta tumor-derived cell line (LUCC8, 
patient 1838) and matched immortalised lymphoblasts (total sample number = 141). Follow-
up ranged from 1-200 months (median 69). 
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Association of Genomic Subtype with Recurrence-Free Survival   
Previously, we identified two copy number groups of stage Ta tumors (Hurst et al., 2012). 
Here, using unsupervised clustering on low pass whole genome sequencing and array CGH 
data on this extended sample series of 141 (including 17 from the previous study), we 
confirmed the existence of two major copy number subtypes (Figure 1A). Seventy-eight 
tumors contained no or few copy number alterations (Genomic subtype 1; GS1). The 
remaining 63, with more alterations, were distinguished primarily by high frequency of 
chromosome 9 deletion, with 9q deletion in all but eight samples (GS2) (Table S1). 
Repeated clustering omitting chromosome 9 showed that potential impact of other common 
regions of copy number alteration was not masked by loss of 9.  
GS2 assignment was strongly associated with the 2004 high grade classification 
(p=0.0053). Disease recurrence occurred in 47.5% of patients (GS1, 45%; GS2, 51%). As 
recurrence is the major clinical problem in NIBC, we examined the relationship of genomic 
subtype to recurrence-free survival (RFS). This revealed a significant difference between 
GS1 and GS2 (p=0.0059) (Figure 1B). We also assessed the relationship of RFS to 9q loss 
and 2004 grade. Both showed associations but these were less significant (Figure 1B). This 
suggests that genomic subtype has clinical relevance and may provide superior prognostic 
information to grade.  
 
Subtype-Specific Gene Expression 
To determine whether there is divergence between GS1 and GS2 tumors at the mRNA 
expression level, we conducted microarray analysis on samples from each class (n=79; 
GS1=48, GS2=31). We identified 363 differentially expressed genes (limma q<0.01), of 
which 21% were upregulated and 79% downregulated in GS2 (Table S2). As expected, the 
majority of differentially expressed genes (n=248) were located on chromosome 9. The 
remainder were scattered throughout the genome (Figure 2A).  
Gene Set Enrichment Analysis showed significant overrepresentation of genes 
involved in mTORC1 signaling (p=0.006) (Figure 2B). This is compatible with loss of one 
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copy of 9q including the mTORC1 negative regulator TSC1 in the majority of GS2 samples. 
Only three GS1 samples had loss of 9q sequences and all retained the TSC1 region. 
Overrepresentation of genes in processes influenced by upregulated mTORC1 signaling 
included those involved in the unfolded protein response (p=0.031) (Figure 2C), cholesterol 
homeostasis (p=0.032) (Figure 2C and D) and glycolysis (p=0.044) (Figure 2C). The same 
processes were identified when chromosome 9 genes were omitted from the analysis 
(p=0.008, 0.012 and 0.031 respectively). 
To examine alignment of the expression profiles of these genomic subtypes with 
previously identified NMIBC expression subtypes, we conducted nearest neighbour analysis 
(knn1) using the Lund dataset of 308 NMIBC and MIBC samples (Sjodahl et al., 2012) as a 
training set. Although our dataset has a distinct composition from this set, the analysis 
indicated that our cohort aligned primarily with the “Urobasal A” subtype (40/48 GS1 and 
24/31 GS2) (Figure S1A) and there was a trend towards membership of the Lund MS1a 
subgroup of Urobasal A in GS1 samples (33/40 GS1 UroA vs 14/24 GS2 UroA; p=0.04). 
Recent RNA-Seq analysis of NMIBC (stage Ta, T1 and CIS) by the UROMOL study 
identified three expression classes (Hedegaard et al., 2016). Implementation of the 
UROMOL 117 gene classifier and subsequent consensus clustering indicated the presence 
of 3+ subtypes in our cohort, and a bias in membership according to GS assignment (Figure 
S1A and S1B). In particular, GS2 samples showed significant bias towards UROMOL class 
2, (p=0.0002). Similarly, nearest neighbour analysis indicated that all samples in this dataset 
align with the UROMOL class 2 subtype. Examination of differential expression between the 
three identified consensus groups and subsequent gene ontology analysis revealed 
enrichment for cell cycle and DNA repair genes (p=2.3e-119 and 3.2e-28 respectively) in the 
class showing a bias for GS2 membership (Figure S1C). This subtype also showed 
increased KI67 labelling index (Figure S1D), which was accompanied by expression of 
CCNB1 in both basal and suprabasal cells of the urothelium (Figure S2). 
No significant enrichment of differentiation or cancer stem cell-associated genes was 
detected. Consistent with this, IHC analysis detected positive staining for the urothelial 
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differentiation-associated markers GATA3, FOXA1 and PPARG that are characteristic of 
luminal/Urobasal A subtypes described by others (Choi et al., 2014; Damrauer et al., 2014; 
Cancer Genome Atlas Research Network, 2014a; Sjodahl et al., 2012) in all GS1 and GS2 
tumors tested (Figure S2). In summary, mRNA profiling of GS1 and GS2 tumors confirmed 
the overall luminal status of the samples and revealed that these subtypes of Ta tumors are 
distinguished by differential mTORC1 signaling. 
 
Mutational Profile  
To determine whether distinct mutational signatures underlie copy number class 
membership, we carried out whole exome and targeted sequencing analysis. Exome 
analysis of 24 samples (17 GS1; 7 GS2) identified 2973 somatic mutations [2851 single 
nucleotide substitutions and 122 insertions or deletions (indels)], with an average of 124 ± 
79 mutations per sample (range 40-285), giving mean and median somatic mutation rates of 
2.41 and 1.64 per megabase (Mb) (Table S3 and Figure S3A). Samples contained an 
average of 119 (37-283) single nucleotide variants and 5 (0-11) indels. Missense, 
synonymous and loss of function mutations (nonsense, frameshift or mutations of the 
invariant dinucleotide at splice junctions) showed averages of 75 (24-180), 25 (9-55) and 14 
(3-27) per sample respectively (Figure S3A). 
Overall, 47% of nucleotide substitutions were C>T transitions, followed by C>G 
transversions (24.8%) (Figure S3B). Enrichment of a mutational signature compatible with 
the action of the APOBEC family of cytidine deaminases (Burns et al., 2013; Roberts et al., 
2013) is prevalent in both MIBC (Cancer Genome Atlas Research Network, 2014a) and 
NMIBC (Acar et al., 2015; Hedegaard et al., 2016; Nordentoft et al., 2014). Here, 18 
samples (75%) had up to 5-fold enrichment of this signature (Figures 3A and S3C). The 
fraction of these mutations reached 60% in some samples and APOBEC signature 
mutations represented 35% of all mutations. APOBEC cytidine deaminase(s) can cause 
mutations only in G:C base pairs. The number of these mutations and of mutations with 
stringent APOBEC signature strongly correlated with the total number of mutations in each 
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sample except in two outliers (Figure S3D), one of which contained two POLE missense 
mutations (1117), the other a missense mutation in POLE2 (1058). 
Nonsynonymous mutations were present in 1949 genes, 208 of which were mutated 
in ≥2 samples. Inactivating mutations were present in 286 genes, 21 of which showed 
mutation in more than one sample (Table S3). GenomeMuSic analysis (Dees et al., 2012) 
revealed significant mutation rates in the order PIK3CA, FGFR3, KDM6A, STAG2, HRAS, 
EP300, RHOB and ARID1A (Table S4). Three samples showed missense mutations in 
RHOB, two of which were identical (E47K). Other genes, including chromatin modifiers 
KMT2A, KMT2D and UTY, the RNA-binding protein RBM10, and BRCA2, showed ≥ 3 
mutations but did not reach statistical significance. The majority of mutations in chromatin 
modifier genes including KDM6A, KMT2D, KMT2C, CREBBP, EP300, ARID1A and STAG2 
were inactivating (Figure S4A). 
The frequent loss of chromosome 9 in bladder cancer has led to many studies aimed 
at identifying candidate tumor suppressor genes. Two 9q genes, TSC1 and NOTCH1, are 
inactivated by mutation in bladder cancer (Platt et al., 2009; Rampias et al., 2014). As the 
detected mutation frequencies of these genes are significantly lower than the overall 
frequency of 9q loss, it is possible that other 9q target genes remain to be identified. Eight 
samples analysed by exome sequencing had copy number loss of 9q. One of these had a 
nonsense mutation in TSC1 but no mutations were identified in NOTCH1.  No other 9q gene 
was mutated more than once.  
To determine if particular gene categories were significantly over-represented, we 
conducted unbiased Gene Ontology analysis, using genes mutated in two or more samples 
as input. Two gene ontology networks featuring purine nucleoside binding (including RHOB) 
(p=1.20 E-06) and chromatin modification (p=9.92 E-07) dominated. Forty-nine genes were 
selected to determine prevalence in an additional 58 samples using custom target capture. 
Selection was based on significance, frequency of mutation in the discovery series, type of 
mutation, known functional roles, and comparison with the Cancer Gene Census (Futreal et 
al., 2004) (Table S4).  FGFR3, KRAS, NRAS, HRAS and TP53 mutation data were acquired 
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independently. Nonsynonymous mutations in 28 genes were identified in ≥ 5% of samples. 
Data for these genes in the 82 tumors analysed by exome and targeted sequencing is 
shown in Figure 3B.  
Strikingly, 17 of 48 mutations in PIK3CA were not in the major hotspot codons (E542, 
E545, H1047) identified in bladder and other tumors (Platt et al., 2009). Several of these, 
including 4 of 5 in the C2 domain, have been reported in other tumor types, two of which 
(N345K, C420R) have experimentally confirmed gain of function (Gymnopoulos et al., 2007) 
(Figure S4B). 
Mutations in KMT2C and KMT2D were significantly concordant (p=6.61E-05, 
FDR<0.05) (Figure S5), illustrating lack of redundancy between these components in this 
context. As observed previously (Jebar et al., 2005), RAS and FGFR3 mutations were 
mutually exclusive (p=7.47E-11, FDR<0.05). We also observed mutual exclusivity between 
RAS and KDM6A mutations (p=1.10E-03), likely reflecting the common co-occurrence of 
KDM6A and FGFR3 mutations (p=2.06E-03) (Figure S5).  
Ten somatic mutations in BRCA2 were identified in eight samples. Two of these are 
predicted to be pathogenic (nonsense). Three of the 7 missense variants were predicted as 
deleterious or potentially deleterious using SIFT (Kumar et al., 2009) and/or PolyPhen  
(Adzhubei et al., 2013) algorithms, one of which (T2662K) has been reported as pathogenic 
when found in the germline (Shirts et al., 2016). We also assessed germline sequences and 
identified one potentially pathogenic variant (rs11571833; K3326*) in a patient with a 
somatic mutation (Table S5). This variant has previously been associated with risk of breast 
and ovarian cancer (Meeks et al., 2016). Four missense variants were present in both 
germline and tumor DNA, of which 3 were predicted to be deleterious; none of these have 
been reported as pathogenic. 
 
Relationship of Genomic Class to Mutational Landscape  
We examined mutation frequency, mutation signatures and affected genes in the 
context of copy number class membership. Mutation rate per megabase derived from whole 
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exome sequencing data was higher in tumors assigned to GS2 (Mean 1.85 vs 3.75; 
p=0.0013) (Figure 4A). Consistent with this, GS2 tumors were also more likely to contain 
significant APOBEC-related signatures (Figure 4B). APOBEC3H was the only member of 
this gene family that showed differential transcript levels between the two copy number 
classes (Figure 4C). We examined the possibility that the detected difference in mutation 
frequency could in part be due to mutations in DNA repair genes. Mutations in candidates 
such as BRCA2 were equally distributed in the two classes. A few genes (e.g. UEVLD, 
USP47) were exclusively mutated in one class and not the other, but the total number of 
mutations in these genes was low (n=3 and 4 of 82 respectively). We assessed the 
relationship between specific mutations and RFS, and no associations were found (p>0.05; 
q>0.01). 
FGFR3 and PIK3CA mutation frequencies were not significantly different in the two 
subtypes, though HRAS mutations were more frequent in GS1 (20% vs 3%; p=0.021) 
(Figure 4D). Consistent with mTORC1 pathway gene expression enrichment in GS2, 
mutations in TSC1 were more common in GS2 (Figure 4E) (4% in GS1 vs 19% in GS2; 
p=0.0383). Mutations in many genes associated with chromatin regulation were present in 
both genomic subtypes (Figure 4F and G). However, STAG2 mutations were more frequent 
in GS1 (46% vs 25%) (Figure 4G). This higher frequency of STAG2 inactivation in GS1 was 
confirmed by immunohistochemistry with 33% of GS1 tumors showing no positive staining in 
contrast to 20% of GS2 (not shown).  
 
Comparison of the Mutational Landscape of Non-Invasive and Muscle-Invasive 
Bladder Cancer  
We compared mutation frequencies in NIBC with those found in MIBC (Cancer Genome 
Atlas Research Network, 2014a) (http://www.cbioportal.org/public-portal/index.do).  This 
revealed both known differences, including absence of TP53 mutations and high frequency 
of FGFR3, PIK3CA and STAG2 mutations in stage Ta tumors, and a significantly higher 
mutation frequency of KDM6A, RAS, RHOB and UNC80 in NIBC (Figure S6). Notable 
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absences from the list of mutated genes in stage Ta tumors apart from TP53, are CDKN1A, 
RB1, ERCC2, ERBB3 and FBXW7, which are mutated in >10% of MIBC (Cancer Genome 
Atlas Research Network, 2014a). 
 
Structural and Functional Analysis of RHOB Mutations  
We found mutations in the Ras superfamily GTPase member RHOB at significantly higher 
frequency (13.4% overall; 15% of GS1; 11% of GS2; Figure 3B) than reported in MIBC (5%) 
(Cancer Genome Atlas Research Network, 2014a). To explore the mutation spectrum further 
and to determine whether mutation is more common in NMIBC overall, we screened 36 
stage T1 tumors by direct sequencing. This identified 6 additional mutations (overall 
frequency, 12.7%). Whilst missense variants were in several “hotspots” (Figure 5A), there 
was also a large deletion that includes the “insert region”, an alpha-helical structure that in 
RHOA is essential for Rho kinase activation and cell transformation (Zong et al., 2001). A 
subset of missense mutations is located in regions of the protein implicated in interaction 
with PKNs 1-3 (Hutchinson et al., 2013) (Figure 5B and C). Overall, the mutations mapped 
to two separate regions of the RHOB protein, which broadly correspond to the two contact 
sites for PKN1 HR1 domains observed in the structure of the RHOA-PKN1 HR1a complex 
(Maesaki et al., 1999). Glu32 is in the switch 1 region and although it does not directly 
contact PKN1 it is likely to alter the interaction of Glu29. The finding of a large deletion, 
together with reports that RHOB has a tumor suppressor function (Huang and Prendergast, 
2006), suggested that these may be inactivating mutations. We transiently expressed HA-
tagged WT and mutant forms (E32K, E47K and E172K) with PKNs 1, 2 or 3 in HEK293 cells 
to assess interaction. Co-immunoprecipitation confirmed interaction with WT RHOB and 
some interaction with all mutants tested (data not shown). However low-level expression of 
mutant proteins in repeated experiments suggested that these forms may be unstable. This 
was confirmed by cycloheximide chase assays where the half-life of WT RHOB was 
measured as 50-60 min and E32K, E47K and E172K showed half-lives of ≤ 20 min (Figure 
5D).  
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Mutations in Chromatin Modifier Genes 
Of 633 confirmed chromatin modification (CM) genes in the DAnCER database 
(http://wodaklab.org/dancer/) (Turinsky et al., 2011), 84 genes showed non-silent mutations 
in samples analysed by exome sequencing (Table S6). Of these, 25 had inactivating 
mutations. Overall, 59 of 154 (38%) nonsynonymous mutations in these genes were 
inactivating (Table S3). All exome-sequenced tumors showed mutation in ≥ 2 CM genes 
(range 2-16; median 6) and 21 (87%) had inactivating mutations in ≥ 1 CM gene (range 1-5; 
median 2). 
 Of 17 CM genes analysed by target capture (Table S4), 11 showed ≥ 5% non-silent 
mutations (Figure 3B). Ninety-one percent of tumors had one or more mutations in these 
genes and 68% had 2 or more. Most frequently mutated CM genes were KDM6A, STAG2, 
KMT2D, EP300, ARID1A, KMT2C and CREBBP (Figures 6A, 6B and S4B). The H3K4 
methyltransferases encoded by KMT2C/D and H3K27 demethylase encoded by KDM6A are 
part of a COMPASS-like complex associated with creating permissive chromatin 
environments at enhancers (Hu et al., 2013). Inactivating mutations in these genes suggest 
that altered chromatin remodelling and aberrant gene silencing accompanies transformation 
in these tumors. At least one of these genes was mutated in 70% of NIBC. 
 
Association of KDM6A Mutation with Female Gender 
Bladder cancer has a male:female incidence ratio of approximately 3:1 (Fajkovic et al., 
2011) that is not fully understood (Reviewed in (Dobruch et al., 2015)). Differences in 
smoking habits are insufficient to account for this and suggested hormonal effects remain 
unclear. Molecular differences between tumors in males and females have not been 
explored extensively. Previously, we reported that STAG2 (Xq25) mutation was associated 
with female gender in a study of tumors of all grades and stages (Taylor et al., 2013), but 
this was not confirmed here (p=0.3). An association of male gender with mutation in the RNA 
splicing gene RBM10 (Xp11.23) has been reported in lung adenocarcinoma (Cancer 
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Genome Atlas Research Network, 2014b), but we found no gender-related difference (11% 
in females; 9% in males). However, we identified a striking association between KDM6A 
(Xp11.2) mutation and female gender (p=0.0092). Such a relationship has not been reported 
in other cancer types and interrogation of data from MIBC (Cancer Genome Atlas Research 
Network, 2014a) did not reveal a similar association. Mutations found in KDM6A are shown 
in Figure 6A. 
Overall, 20 of 27 samples from female patients (74%) contained at least one KDM6A 
mutation. This gene is not X-inactivated (Greenfield et al., 1998) and, compatible with its 
predicted tumor suppressor function, 7 female samples had two mutations in the gene. In all 
but one of these, the mutant allele frequency was in the range 35-45%, suggesting that 
these may represent mutations in each of the two alleles. In one case the allele frequencies 
of a missense mutation (R549K) and an essential splice site mutation were ≥ 80%, and 
examination of sequencing read depth indicated likely deletion of one copy, suggesting that 
these may be on the same allele (Figure 6C). Thirteen female samples contained a single 
mutation and examination of read counts in these samples revealed only one additional 
sample with predicted deletion of the WT allele, suggesting that inactivation of a single allele 
in many tumors from females may be sufficient for functional effect.  
In contrast, only 42% of male tumors (23/55) contained a KDM6A mutation. The male 
paralogue UTY (Yq11), which has 83% amino-acid identity with KDM6A (Greenfield et al., 
1998) and has also been shown to have some demethylase activity (Walport et al., 2014), 
may be functionally equivalent to the second KDM6A copy in females. Indeed, we found 
mutation of UTY in 5 of 55 male samples, four of which also had a KDM6A mutation. 
Deletion of UTY in male samples with KDM6A mutation has been found in other cancers 
(van Haaften et al., 2009) and loss of Y is a common event in bladder cancer (Minner et al., 
2010). We examined sequencing read depth in all male samples and identified 14 with 
predicted deletion (25%), 12 of which also had KDM6A mutation (Figure 6C), giving a total of 
47% male samples with inactivation of one or both genes.  
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As KDM6A participates in COMPASS-like complexes with the chromatin methyl 
transferases KMT2C and KMT2D (Ford and Dingwall, 2015), which were mutated in 15% 
and 30% of these samples respectively, we examined the relationships of mutations in these 
genes, KDM6A and UTY and their combinations in relation to gender. In females, the 
majority of mutations in these genes occurred in conjunction with KDM6A mutation, with only 
8% of samples showing independent mutations (Figure 6D). In contrast, 22% of male 
samples carried KMT2C and/or KMT2D mutations in the absence of KDM6A and/or UTY 
mutation or deletion. 
 
DISCUSSION 
NIBC are the most prevalent bladder tumors with urgent needs for improved prognostic 
biomarkers and approaches to localised therapy. We aimed to obtain more comprehensive 
genomic information and seek features that might allow these needs to be addressed. All 
samples initially selected for analysis were stage Ta primary tumors with predominantly 
papillary architecture, 95% classified as grade 2 (WHO, 1973), 61% as low and 39% as high 
grade according to the 2004 classification (Eble et al., 2004). No grade 3 tumors were 
intentionally included, but three were re-graded as grade 3 upon evaluation by a single 
pathologist. As such, this series represents the major population of stage Ta tumors at 
diagnosis. All expression profiling studies of bladder cancer identify a subtype with features 
similar to luminal breast cancer that expresses GATA3, FOXA1, and PPAR?, and all tumors 
here expressed these genes, confirming them as luminal. 
We define two genomic subtypes, one (GS2) with reduced recurrence-free survival. 
Many GS1 tumors had no detectable copy number alterations, whereas most GS2 tumors 
showed loss of 9q. Although 9q loss is suggested as an early event in bladder cancer 
development, this was not a common solitary event, but rather the most frequent alteration 
in a general pattern of chromosomal instability, within which we did not identify other 
common features. One confirmed 9q deletion target is TSC1, but this does not account for 
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the loss of the entire chromosome arm in most cases. However, we found no evidence for 
other mutational targets, suggesting that haploinsufficiency for 9q genes may be important.   
Expression profiling has uncovered clinically important bladder tumor subtypes. The 
tumors analysed here showed strong alignment to the Urobasal A subgroup (Sjodahl et al., 
2012) and we suggest that addition of genomic information may provide prognostic 
information for this large tumor group. Consensus clustering and nearest neighbour analysis 
showed alignment of GS2 to the UROMOL class 2. Although this UROMOL class showed 
highest risk for progression, this was related to a large number of stage T1 tumors in class 2 
(Hedegaard et al., 2016). Thus we suggest that alignment of GS2 Ta tumors to this class is 
unlikely to imply higher progression risk. Only one GS2 sample progressed to muscle 
invasion and one GS1 progressed to stage T1.  
We identified expression features that are predicted to contribute to the observed 
difference in outcome and suggest potential avenues for therapy. Key hallmarks of GS2 
were upregulated DNA repair and mTORC1 signaling and downstream effects of mTORC1 
signaling, likely due to deletion or mutation of TSC1. mTORC1 stimulates anabolic 
processes including mRNA translation, aerobic glycolysis and de novo lipid and nucleotide 
synthesis (Saxton and Sabatini, 2017). Deregulated protein synthesis resulting from 
constitutive mTORC1 activity leads to endoplasmic reticulum (ER) stress that triggers the 
unfolded protein response, as seen in cells from Tsc1/2 deficient mice (Ozcan et al., 2008) 
and observed here in GS2. mTORC1 is also implicated in upregulation of genes involved in 
fatty acid synthesis (e.g. SCD, FASN), and cholesterol biosynthesis and homeostasis in 
GS2. Upregulated genes are involved in both cellular uptake of LDL-cholesterol (LDLR) and 
de novo cholesterol biosynthesis (ACAT2, HMGCS, HMGCR, IDI1, FDPS, SQLE, LSS, 
CYP51A1). FGFR3 activation also stimulates lipogenesis (Du et al., 2012), but as the 
majority of both GS1 and GS2 tumors contained activating FGFR3 mutations, we conclude 
that the increase in GS2 results from mTORC1 activation. GS2 also showed a hypoxia-
related signature, attributed to the effect of mTORC1 on translation of hypoxia-inducible 
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factor 1? (HIF1?). Glycolysis supplies both energy and precursor molecules including 
pyruvate, which can be converted to acetyl-coA, the precursor for cholesterol synthesis.  
This reprogramming generates a state of metabolic vulnerability. Tsc1/2 deficient 
mouse cells are vulnerable to ER stress-induced apoptosis due to inability to adapt to 
additional ER challenge (Di Nardo et al., 2009; Ozcan et al., 2008) and are sensitive to ER 
stress inducers such as thapsigargin and tunicamycin (Ozcan et al., 2008). Such cells also 
succumb to additional oxidative stress (Li et al., 2016; Medvetz et al., 2015) and as 
mTORC1 inhibits autophagy, they are also vulnerable to further autophagy inhibition 
(Parkhitko et al., 2014). Drugs that target cholesterol synthesis or transport (Kuzu et al., 
2016) may also have activity. Whilst some of these drugs may be toxic systemically, use as 
intravesical agents may be possible in NMIBC and some may have application in 
combination with rapalogues in systemic treatment of TSC1-deficient MIBC. 
Despite similar patient age and smoking status, the overall mutation load in NIBC 
was approximately three-fold lower than reported in MIBC where an average of 7.7 (median 
5.5) mutations per Mb was reported (Cancer Genome Atlas Research Network, 2014a). As 
APOBEC mutagenesis plays a major role in both groups (Acar et al., 2015; Hedegaard et 
al., 2016; Lamy et al., 2016; Cancer Genome Atlas Research Network, 2014a; Nordentoft et 
al., 2014), other factors may contribute to mutational burden in MIBC. Enrichment of 
APOBEC mutational signatures in NMIBC has been associated with high-risk tumors 
(Hedegaard et al., 2016; Lamy et al., 2016) and, compatible with this, we found enrichment 
in GS2, associated with higher APOBEC3H (A3H) expression. A3H is polymorphic, with 
seven haplotypes (A3H1-7), and in APOBEC3B-null breast cancers the A3H-1 haplotype 
contributes to the bulk of APOBEC signature mutations (Starrett et al., 2016). Here, we 
found no evidence for an association between A3H haplotype and APOBEC mutagenesis 
(data not shown). It is likely that the upregulated expression of DNA repair genes identified 
here contributes to the mutational burden and genomic instability of GS2 tumors. We also 
hypothesise that mutations in DNA repair genes play a larger role than we detected. 
Mutations in ERCC2 were reported recently in 11 of 32 high-grade Ta samples (Pietzak et 
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al., 2017). We found one missense mutation in ERCC2, one in ATM, one in FANCD2 and two in 
FANCM in exome-sequenced samples. These genes were not included in our custom target 
capture but should be included in future analyses. 
NIBC are characterised by frequent activating mutations in FGFR3 and PIK3CA. Most 
screens for PIK3CA mutations examine only hotspot codons. Our finding of many non-
hotspot mutations indicates that the frequency of mutation in bladder cancer is higher than 
reported to date and that future mutation screening should examine the entire gene. 
Interestingly, many tumors in both genomic subtypes had PIK3CA activating mutations, 
indicating that this is not directly related to the activated mTORC1 profile in GS2, and as 
reported previously (Platt et al., 2009), TSC1 and PIK3CA mutations were not mutually 
exclusive. 
Although a limitation of this study is its power to detect infrequently mutated genes, it 
is clear that these tumors form a more homogeneous group than MIBC, where only TP53 is 
mutated in more than 30% of cases and there is a long “tail” of infrequent mutations (Cancer 
Genome Atlas Research Network, 2014a). Nevertheless, we found differences between the 
subtypes, including more mutations of HRAS and STAG2 in GS1 and of TSC1 in GS2. 
Mutations in chromatin regulators were present at higher frequencies than in MIBC. All 
tumors had mutations in 2 and often many CM genes, with KDM6A and STAG2 most 
frequently mutated, both at higher frequency than in MIBC.  
The mutation frequency of the small GTPase RHOB was also higher than in MIBC 
(13% vs 5%) (Cancer Genome Atlas Research Network, 2014a). RHOB levels are 
decreased in many cancers including bladder (Volanis et al., 2011) and ectopic expression 
can suppress the transformed phenotype (Huang and Prendergast, 2006). The mutant forms 
of RHOB were less stable, suggesting a tumor suppressor function of WT RHOB in the 
urothelium. GTP binding drives a conformational change in RHOB that permits interaction 
with effectors such as the PKN family of serine threonine kinases (Hutchinson et al., 2013) 
and our structural analysis predicts that the mutant RHOB proteins described might exhibit 
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reduced interaction with PKN. Thus, in addition to reducing RHOB stability, RHOB mutants 
may be further impaired in signaling through reduced interaction with their effectors. 
Although bladder cancer incidence is 3-4 times higher in males than in females, 
women with MIBC have worse outcomes than males (Reviewed in (Marks et al., 2016)). 
There is little data for NIBC, though a preponderance of grade 1 in females has been 
reported (Thorstenson et al., 2016). Overall, we found a trend towards GS1 membership in 
female samples in this series (p=0.049). 
We speculate that some of the proposed influences on incidence might lead to 
gender-related molecular differences and consequent differences in tumor phenotype and 
clinical behaviour. Our finding of more KDM6A mutations in female NIBC is the most 
significant gender-related molecular difference reported to date. We sought evidence for a 
similar gender relationship in published studies. None is apparent in MIBC (Gui et al., 2011; 
Guo et al., 2013; Cancer Genome Atlas Research Network, 2014a). Relatively few NIBC 
have been screened for mutations, but in a series of exome-sequenced recurrent NMIBC 
there appears to be a skew towards female patients (Lamy et al., 2016) and a similar skew 
is apparent in a study of tumors of all grades and stages (Ahn et al., 2016). However, a 
recent study that included 51 stage Ta samples from patients in Singapore and Taiwan 
showed no gender bias (Ler et al., 2017). The reason is unclear but could relate to 
geographical or grade differences in the patient populations or the different methods used. A 
major limitation of all studies is the small number of female samples analysed and this is 
more acute if there is indeed a relationship to tumor grade and stage. Examination of a large 
series of tumors of all grades and stages using a standardised mutation screening approach 
is required to confirm this gender difference and its relationship to tumor histopathology. 
Studies of other tumor types report a bias towards mutation of KDM6A in males (Van 
der Meulen et al., 2015; van Haaften et al., 2009), compatible with the presence of a single 
allele in males and its escape from X-inactivation in females (Greenfield et al., 1998). Thus, 
our finding is counterintuitive. However, biallelic mutation was not detected in the majority of 
females, suggesting that KDM6A may be haploinsufficient in the female urothelium. The 
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protein encoded by UTY in males has some demethylase activity but not full functional 
equivalence to KDM6A (Walport et al., 2014). This is compatible with our finding of UTY 
mutation or deletion in several male samples, though the overall frequency of involvement of 
either of these genes (47%) was lower than that of KDM6A mutation in females. 
KDM6A is implicated in transcriptional regulation at promoters and enhancers (Van 
der Meulen et al., 2014) and loss of its demethylase activity on H3K27 and H3K4 is 
predicted to lead to transcriptional repression. There is also evidence for enzyme-
independent functions of KDM6A. Thus the consequences of inactivation may be 
multifaceted and likely to be urothelial cell context dependent. Whether there are gender-
related epigenetic differences in the normal urothelium is unknown, but if KDM6A has a 
gender-related role in these cells, this could influence the early tumor pathogenesis 
pathway. 
In summary, these data provide an improved view of the genomic landscape of NIBC 
that points to chromatin modification as a key oncogenic driver for future therapeutic 
evaluation and to metabolic vulnerability as a therapeutic target in tumors with loss of 9q. 
Our results also highlight the potential need for gender stratification in an era of precision 
oncology. 
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FIGURE LEGENDS 
Figure 1. Copy Number Subtypes of NIBC and Their Relationship to Recurrence-Free 
Survival 
A. Unsupervised hierarchical cluster analysis of copy number data from 140 Ta tumors and 
LUCC8 cell line. Columns represent samples and rows genomic position. Blue, copy number 
gain; yellow, copy number loss. Chromosome number is shown on the left-hand side. Two 
main clusters, GS1 and GS2, are indicated.  
B. Kaplan-Meier plot of recurrence-free survival (RFS) in patients stratified according to 
genomic subtype (GS1 n=78; GS2 n=61), 9q loss (no loss n=82; loss n=57) and 2004 grade 
(low n=86; high n=53). A log-rank test reveals statistically significant differences. 
See also Table S1. 
 
Figure 2. Analysis of mRNA Expression in GS1 and GS2 
A. Heatmap representation of gene z-scores detected as differentially expressed (limma; p 
value and FDR <0.01) between GS1 (n=48) and GS2 (n=31) using expression microarray 
analysis. Genes located on chromosome 9 are indicated by sidebar. 
B. Gene Set Enrichment Analysis results depicting differential expression of genes 
associated with mTORC1 signaling (nominal p=0.006) between GS1 and GS2. 
C. Heatmap representations of gene z-scores associated with Gene Ontology Biological 
Processes that differ significantly between GS1 and GS2 samples. 
D. mRNA expression levels (log2) of selected cholesterol (SQLE) and lipid biosynthesis 
(FASN) genes that were significantly differentially expressed (p<0.01) between GS1 (n=48) 
and GS2 (n=31) samples. Each box has lines at the lower quartile, median quartile and 
upper quartile values. Whiskers represent the minimum and maximum values. 
See also Table S2 and Figures S1 and S2.  
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Figure 3. APOBEC Signature and Mutations in NIBC 
A. Analysis of an APOBEC mutation signature in exome data from NIBC. Left, distribution of 
the fold of APOBEC mutation pattern enrichment. Enrichment and q values (one-sided 
Fisher’s exact test) were calculated as described previously (Roberts et al., 2013) and in 
STAR Methods. Pie chart shows the distribution of the 24 samples analysed in each 
category. Right, distribution of mutation types in each tumor sample. “APOBEC to G” and 
“APOBEC to T” denote APOBEC induced C to G and C to T substitutions, respectively, in 
TCW motifs, where W represents A or T flanking nucleotides. “Non-APOBEC C:G” denotes 
SNVs in non-APOBEC mutated C:G pairs. “A:T” denotes SNVs in A:T pairs. 
B. Oncoplot showing distribution of mutations in ≥ 5% NIBC. Data is derived from exome 
sequence of 24 samples and selective target capture followed by next generation 
sequencing of 58 additional samples. Chromatin modification genes are shown in bold. 
See also Tables S3-S6 and Figures S3-S6. 
 
Figure 4. Comparison of Mutations in GS1 and GS2 
A. Boxplot representation of mutations per megabase values based on exome sequence 
analysis of 17 GS1 and 7 GS2 samples plotted according to subtype membership. Mutations 
per megabase values are calculated from number of somatic mutations detected by 
VarScan2 divided by size of genome covered by a minimum of 10 reads in whole exome 
sequencing data. The p values were calculated using Mann-Whitney test. Each box has 
lines at the lower quartile, median quartile and upper quartile values. Whiskers represent the 
minimum and maximum values. 
B. Boxplot representation of APOBEC mutation pattern detection in whole exome sequence 
data (GS1 n=17; GS2 n=7). Fold enrichment is calculated as the number of APOBEC 
signature mutations (TCW to TTW or TGW and the complementary WGA to WAA or WCA) 
divided by the frequency of cytosines in the sequence TCW. The p values were calculated 
using Mann-Whitney test. Each box has lines at the lower quartile, median quartile and 
upper quartile values.  Whiskers represent the minimum and maximum values.  
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C. Dotplot representation of APOBEC3H mRNA expression (log2) (TC22000311.hg) 
detected by microarray analysis of 48 GS1 and 31 GS2 samples. The p values were 
calculated using Mann-Whitney test. Bars represent median, maximum and minimum 
values. 
D-G. Data from combined exome and targeted sequencing of 82 samples was analyzed to 
generate an oncoplot showing distribution of mutations in GS1 and GS2 subtypes in FGFR3, 
PIK3CA and HRAS (D), in TSC1 (E), in histone modifying enzymes (F) and in chromatin 
associated proteins (G). 
See also Table S3.  
 
Figure 5. Structural and Functional Analysis of RHOB Mutations 
A. Schematic of RHOB protein showing mutations found in this study (82 Ta and 36 T1 high-
grade tumors) and in a previous study of MIBC (Cancer Genome Atlas Research Network, 
2014a). G1-G5; G boxes involved in guanine nucleotide binding; switch I and switch II, 
regions that undergo nucleotide-dependent conformational changes. 
B. The structure of RHOB in cartoon form with the positions of the mutations identified. 
Mutated sidechains are shown in a space-filling representation, with carbons in green, 
oxygens red and nitrogens blue. The insert region is indicated. Figure generated using 
Pymol. 
C. The structure of a model of RHOB in complex with PKN1. The HR1 domain in the contact 
1 site is shown in cyan and that in contact 2 is shown in purple. 
D. HEK293 cells were transfected with plasmids encoding WT or mutant (E32K, E47K, 
E172K) RHOB. 24 hr post-transfection, cycloheximide (CHX) (100 μg/ml) was added to 
inhibit protein synthesis. Left panel, whole-cell protein lysates at indicated intervals and 
RHOB expression examined by western blot analysis. Right panel, RHOB expression was 
normalised to α-tubulin and the amount of RHOB protein remaining at each time point 
plotted as a percentage of the level at time point 0 min. 
See also Table S3. 
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Figure 6. Mutation of Chromatin Modifier Genes and Relationship to Gender 
A. Schematic of KDM6A protein showing the distribution and types of mutation identified in 
82 stage Ta bladder tumors. Lower bar is the cDNA sequence with splice site mutations. 
Domain abbreviations: TPR, tetratricopeptide repeat; JmjC, JmjC domain. 
B.  Schematic of histone 3 modification and chromatin remodelling processes dysregulated 
by genomic alterations in 82 NIBC. Increased H3K27me3 (through inactivating mutation in 
KDM6A) or decreased H3K4me3 (through inactivation of KMT2A/2D/2C) is predicted to lead 
to increased chromatin compaction and repression of transcription. These genes are found 
in the same complex and are suggested to have concerted action in regulating transcription. 
76% of tumors in the study showed mutation in at least one of these genes. The 
transcriptional regulator MECOM (EVI1) is implicated in interaction with EP300/CREBBP. K, 
lysine; Me, methylation; Ac, acetylation. Percentages indicate overall frequency of mutation 
in 82 NIBC.  
C. Histograms showing mutant allele frequencies and copy number loss of KDM6A and UTY 
in male and female tumor samples.  
D. Histograms showing distribution of mutations in KDM6A, UTY, KMT2C and KMT2D and 
their combinations in all 82 tumors and separately in tumors from male (n=55) and female 
(n=27) patients. Numbers represent percentages in each group. 
See also Table S3.  
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Further information and requests for resources and reagents should be directed to and will 
be fulfilled by the corresponding author Margaret A. Knowles (m.a.knowles@leeds.ac.uk). 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
 
LUCC8 Cell Line  
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The human bladder cancer cell line LUCC8 was established from a stage Ta grade 2 (TaG2) 
tumor (1838) in this laboratory and maintained in complete Keratinocyte Growth Medium 2 
(Promocell C-20111) supplemented with 0.09 mM [final] CaCl2, 1% FCS and 3 mM glycine 
on BD Primaria plastic (BD Biosciences) under standard culture conditions of 37°C and 5% 
CO2.  Its identity was verified by short tandem repeat DNA typing using the Powerplex 16 
System, which confirmed identity to the original tumor and lack of identity with any other cell 
lines maintained in the laboratory. 
 
Human Tissues and Subject Follow-up Data 
Clinical samples and associated clinical data were sourced from the Leeds Multidisciplinary 
Research Tissue Bank (Leeds East Research Ethics Committee reference: 10/H1306/7). All 
patients gave written informed consent. Cold cup biopsies were collected, snap-frozen and 
stored in liquid nitrogen. The remainder of the sample was embedded in paraffin for 
diagnostic assessment. Samples were graded and staged by a consultant urological 
pathologist (JR) using the 1973 and 2004 WHO and TNM criteria, respectively (Eble et al., 
2004; WHO, 1973). All available clinical information was collected (Table S1). Median follow-
up time was 69 months (range 1-200 months). Copy number analysis was carried out on 
140 grade 1 or grade 2 stage Ta tumors and the LUCC8 (1838) cell line. Twenty-three of 
these tumors and the LUCC8 cell line were used for whole-exome sequencing, 58 tumors 
were used for targeted re-sequencing and seventy-nine tumors were gene expression 
profiled. Details of the platforms each sample was analysed on are given in Table S1. Thirty 
six stage T1 high grade tumors were included in analysis of RHOB mutation only. No other 
clinical information was collected for these samples.  
 
HEK293 cells 
HEK293 cells were maintained in DMEM (high glucose) containing 10% fetal calf serum 
under standard culture conditions of 37?C and 5% CO2.  
 
METHOD DETAILS 
 
DNA Extraction 
Genomic DNA was isolated from frozen tissue sections comprising at least 70% tumor cells 
using a QIAamp DNA Mini Kit or a Gentra PureGene Tissue Kit. DNA was extracted from 
Venous blood samples using a Nucleon BACC DNA Extraction Kit or by salt precipitation. 
 
Copy Number Analysis 
Low pass whole genome sequencing or array-CGH was used to assess copy number 
alterations in 141 grade 1 or grade 2 stage Ta primary tumors and the LUCC8 cell line. Next-
generation sequencing libraries were constructed using NEBNext? reagents according to 
the manufacturer’s instructions. Raw sequencing data was processed as described in the 
“Read mapping and genotype calling” section. After BAM file generation, ngCGH was used 
to compare number of read counts between tumor and matched blood samples using a 
window size of 1000 reads (Gartner et al., 2012). GC correction and copy number calling 
using the FASST2 Segmentation Algorithm, a Hidden Markov Model (HMM) based 
approach, were carried out within the Nexus Copy Number software package. The 
significance threshold for segmentation was set at 1.0E-5 also requiring a minimum of 3 
probes per segment and a maximum probe spacing of 1000 between adjacent probes 
before breaking a segment. The log ratio thresholds for single copy gain and single copy 
loss were set at 0.2 and -0.2, respectively. The log ratio thresholds for two or more copy gain 
and homozygous loss were set at 1 and -1 respectively.  Array-CGH and copy number 
calling was carried out as previously described (Hurst et al., 2012). To conduct cluster 
analysis, each individual region associated with a BAC array clone was assigned a copy 
number class (0 = no copy number alteration; 1 = gain; 2 = high-level amplification; -1 = loss; 
-2 = high-level loss). One-way unsupervised hierarchical cluster analysis was conducted 
using Euclidean distance and the Ward method of linkage. 
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RNA Extraction and Gene Expression Profiling 
Seventy-nine tumors were expression profiled (Table S1). Total RNA was isolated from 
frozen tissue sections using a RNeasy Plus Micro Kit and amplified using the Affymetrix 
GeneChip® WT PLUS Reagent Kit according to manufacturer’s instructions. The resulting 
cDNA was quantified using OD (NanoDrop). The cDNA was normalised and hybridised onto 
Affymetrix Human Transcriptome 2.0 microarrays for 16 hr at 45°C. Microarrays were 
washed and stained using the Affymetrix GeneChip® Hybridization, Wash, and Stain Kit 
according to manufacturer’s instructions using the Affymetrix GeneChip® Fluidics Station 
450. Microarrays were scanned using an Affymetrix GeneChip® 7G microarray scanner. 
Quality control checks, gene level normalization (using SST-RMA) and signal summarisation 
was conducted using Affymetrix® Expression Console™ Software. R2 was used for routine 
data visualization. The UROMOL classifier was implemented by selection and median-
centering of each of the 117 genes, then 1000 iterations of ConsensusClusterPlus (CCP) 
(Wilkerson and Hayes, 2010) v1.36.0 were run using a Pearson distance metric and a 
random gene fraction of 0.8 (Hedegaard et al., 2016). For comparison to previously 
published LUND subtypes we used 1-Nearest Neighbour Classification test from the R 
package “class” (v 7.3-14); 956 genes were shared between array technologies. Data from 
all 308 tumors (GSE32894) was used as a training set against data described here. GSEA 
v2.2.1 was carried out using all genes; genomic subtypes were assigned as phenotypes and 
permuted 1000 times, the test dataset was collapsed to gene symbols and run against gene 
sets in the Hallmarks database. 
 
Immunohistochemistry 
For immunohistochemistry, fixed paraffin embedded tissues were sectioned at a thickness of 
5 ?M and mounted onto slides. Slides were heated for 20 min at 70?C then deparaffinised in 
100% xylene (three times for 3 min), rehydrated in 100% ethanol (four times for 1 min), and 
finally washed once in water to remove excess ethanol. Antigen retrieval was carried out 
using the Menarini antigen retrieval unit (Menarini Diagnostics). Slides were heated in citrate 
buffer (pH6) to 125?C for 2 min, then briefly washed in 1x tris-buffered saline (TBS) 
automation wash buffer (Menarini Diagnostics). Slides were then rinsed under running water 
before washing in TBS for 30 s and Menarini wash buffer (Menarini Diagnostics) for 30 s. 
Endogenous peroxidase and alkaline-phosphatase activity was blocked with 2 drops of 
Bloxall blocking solution (Vector Laboratories) for 10 min. Non-specific antigen binding was 
blocked by incubation in a 10% casein solution in antibody diluent (Invitrogen) for 20 min. 
Sections were stained for CD45, GATA3, FOXA1, KI67, CCNB1, PPARG, STAG2 and 
UPKIII. All runs included a no primary antibody control. Primary antibodies were diluted in 
antibody diluent (Invitrogen) and applied to slides for 1 hr at RT. Slides were washed twice in 
1x TBS automation wash buffer (Menarini Diagnostics). Post-primary HRP conjugated 
antibodies were added using a Novocastra post-primary blocking kit (Leica Biosystems). 
Slides were incubated with 2 drops of post primary reagent (Leica Biosystems) for 30 min, 
then washed twice in 1x TBS automation wash buffer (Menarini Diagnostics) for 5 min 
before 2 drops of polymer reagent (Leica Biosystems) was added. Slides were washed twice 
in TBS for 5 min. Detection was performed using DAB peroxidase substrate (Vector 
Laboratories). Two hundred microliters of ImmPACTTMDAB substrate was applied to each 
slide for 5 min. Each slide was transferred to a water reservoir for 5 min before 
counterstaining in haematoxylin for 30 s. Slides were then washed in running water for 1 
min, Schotts water for 1 min, 100% ethanol once for 15 s, 100% ethanol once for 2 min, and 
100% ethanol twice for 3 min, and immersed in 100% xylene (three times for 3 min). 
Coverslips were mounted on the slides with DEPEX (Fisher Scientific UK Ltd) and slides 
were visualised using an Olympus Bx50 microscope (Olympus Optical Co.). 
Exome Sequencing 
Twenty-three tumors and the LUCC8 cell line and their matched blood samples were 
analysed by whole-exome sequencing. Libraries were generated using 3 μg of DNA and 
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enriched for exonic regions using the SureSelect Human All Exon 50Mb kit (20 tumor/blood 
pairs) or the SureSelect Human All Exon V4 Kit (4 tumor/blood pairs) according to the 
manufacturer’s protocols. Sequencing was performed by Oxford Gene Technology (Oxford, 
UK) on an Illumina HiSeq 2000 in paired-end mode with 100bp read length and eight 
samples (four tumor/blood pairs) per lane. Base calling and quality control was performed 
using Illumina’s Real Time Analysis software version 1.6 with standard settings. Sequence 
files were QC checked using FastQC (v0.10.0) before preprocessing. Adapter contamination 
and low-quality read ends (< 20) were trimmed using cutadapt 1.3. Any read in which either 
pair had a length less than 19 was removed from subsequent analysis. 
 
Read Mapping and Genotype Calling 
Alignment was performed using BWA 0.7 to hs37D5, the GRch37/hg19-based reference 
used by the 1000 Genomes Project. Duplicate reads were removed using the Picard v1.56 
MarkDuplicates program. Local realignment around indels was performed using the GATK 
v1.3 RealignerTargetCreator and IndelRealigner in Smith-Waterman mode with reference to 
dbSNP v132.  The Picard v1.56 FixMateInformation program was used to ensure that all 
mate-pair information was in sync between each read and its mate following local 
realignment. Base quality scores were recalibrated using GATK v1.3 CountCovariates and 
TableRecalibration with reference to dbSNP v132. BAM files were sorted and then indexed 
using SAMtools index. Sequencing metrics were generated using the Picard v1.56 
CalculateHsMetrics programme with intervals files relevant to capture regions for either 
SureSelect Human All Exon 50 Mb or SureSelect Human All Exon V4. 
 
Somatic Variant Analysis 
Pileup files (created using SAMtools mpileup, with parameters – d 5000 and q- 20) were 
used as input to VarScan2 v2.3.5. This was used in somatic mode, with a strand filter, to 
identify somatic single nucleotide variations and small insertions and deletions (indels). 
Results were then processed using processSomatic to extract the somatic mutations with 
the specification that zero reads were to support the variant in the normal (matched blood) 
sample. High confidence somatic variant and indel calls were converted to mutation 
annotation format (MAF) using a bespoke script that accesses Ensembl version 75 via the 
application programming interface. 
 
Validation of Mutation Calls 
Primers were designed using BatchPrimer3 (http://probes.pw.usda.gov/cgi-
bin/batchprimer3/batchprimer3.cgi?). PCR was performed in a volume of 15 μl containing 1 x 
PCR buffer, 1.5 mM MgCl2, 200 μM dNTPs, 0.2 μM each primer, 1U AmpliTaq Gold and 10 
ng of genomic DNA. Cycle parameters were 95?C for 5 min then 35 cycles of 95?C for 45 s, 
55?C for 45 s and 72?C for 45 s followed by 72?C for 10 min. 5 µl of PCR products were 
mixed with 2 µl of illustraTM ExoProStar and incubated at 37?C for 15 min, then 80?C for 15 
min. Sequencing was performed using 1 µl of ExoProStar-treated PCR product and a Big 
Dye Terminator Ready Reaction Mix v1.1 kit. A total of 193 somatic single nucleotide 
variants identified by whole-exome sequencing were examined using this approach. Of 
these 178 variants (92%) were confirmed, 1 variant was not detected and 14 variants could 
not be confirmed due to technical issues with the PCR step. 
 
Mutation Significance Analysis 
Significantly mutated genes were identified using the Genome MuSiC package. The genome 
music bmr calc-covg script was run to count the bases with sufficient coverage in the regions 
of interest (ROIs) of each gene for each pair of tumor-normal BAM files and to categorise 
these base changes into AT, CG (non-CpG) and CpG counts. The script also generates total 
base-counts across all ROIs of each gene for each sample. The MAF file generated during 
the somatic variant calling step and the per-gene coverage data generated by the Genome 
MuSiC bmr calc-covg script were used with the Genome MuSiC bmr calc-bmr script to 
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calculate the overall Background Mutation Rate (BMR) and BMRs of different mutation 
categories (AT/CG/CpG transitions, AT/CG/CpG transversions, and indels). The output file 
generated by the Genome MuSiC bmr calc-bmr script contains per-gene mutation rates and 
this was used with the Genome MuSiC smg tool to test for significantly mutated genes. 
Using the per-gene mutation rates categorized by mutation type and the overall background 
mutation rate for each category, Genome MuSiC smg calculates p values and false 
discovery rates (FDR) for each gene using three tests (Fisher’s Combined p value Test 
(FCPT), Likelihood Ratio Test (LRT), and the Convolution test (CT)). If the FDR of a gene 
was less than the specified maximum FDR for at least two of the tests, then the gene was 
considered significantly mutated. 
 
Analysis of APOBEC Mutagenesis Signature 
The exome-wide prevalence of the APOBEC mutagenesis signature and the enrichment of 
this signature over its presence expected for random mutagenesis was evaluated as 
described in (Roberts et al., 2013) and in (Chan et al., 2015). Analysis results are 
summarised in Table S3.  Briefly, analysis is based on previous findings that APOBECs 
deaminate cytidines predominantly in a tCw motif and that the APOBEC mutagenesis 
signature is composed of approximately equal numbers of two kinds of changes in this motif 
– tCw→tTw and tCw→tGw mutations (complements included; flanking nucleotides shown in 
small letters; w=A or T). We calculated on a per sample basis, the enrichment of the 
APOBEC mutation signature among all mutated cytosines in comparison to the fraction of 
cytosines that occur in the tCw motif among the +/- 20 nucleotides surrounding each 
mutated cytosine (“APOBEC enrichment” column). In addition, several other parameters that 
characterize the prevalence of the APOBEC mutagenesis pattern in a sample and/or that 
are useful for downstream analyses and comparisons were calculated.    The most useful 
parameter for studying correlations is the minimum estimate of the number of APOBEC 
induced mutations in a sample - “APOBEC Mutation Load (minimum estimate)” column. It 
was calculated using the formula: [“APOBEC, number of mutations”]x[(“APOBEC 
enrichment”-1)/[“APOBEC enrichment”], which allows estimating the number of APOBEC 
signature mutations in excess of what would be expected by random mutagenesis.  
Calculated values are rounded to the nearest whole number. “APOBEC Mutation Load 
(minimum estimate)” is calculated only for samples passing 0.05 FDR threshold for 
APOBEC enrichment ([“BH_Fisher_p value_tCw”]=<0.05. Samples with “BH_Fisher_p 
value_tCw” value greater than 0.05 receive a value of 0.  The “APOBEC Mutation Load 
(minimum estimate)” value shows high correlation (0.9-0.95) with all other parameters used 
to characterize APOBEC mutagenesis pattern, such as APOBEC enrichment, and absolute 
and relative APOBEC mutation loads. 
 
Targeted Re-Sequencing 
Agilent’s SureDesign tool was used to design a 296 kb SureSelect custom capture for all 
coding exons of the 49 selected candidate genes (Table S4). The design included a 10 base 
pair extension to the 3’ and 5’ ends of each region. Libraries were generated for a validation 
sample set consisting of 58 tumors (Table S1) using 1.2 μg of DNA and enriched for 
targeted exonic regions according to the manufacturer’s protocols. The samples were run in 
a single lane on an Illumina HiSeq 2000 in paired-end mode with 100 bp read length. Raw 
data handling up to FASTQ file generation was as described above. Paired-end files in 
FASTQ format were converted to FASTA format in NextGENe v.2.3.4 (SoftGenetics LLC). 
FASTA reads were quality filtered using the following criteria: median score threshold ≥ 20, 
maximum number of uncalled bases ≤ 3, called base number of each read ≥ 25, and trim or 
reject read when ≥ 3 bases with score ≤ 30. Filtered reads were aligned to a GRch37/hg19-
based human genome reference sequence provided by NextGENe and variants identified 
using mutation calling filters with standard settings (details available upon request). Further 
details relating to file conversion, alignment, and mutation filtering are available at 
http://www.softgenetics.com/PDF/NextGene_UsersManual_web.pdf. The NextGENe Viewer 
(Softgenetics) was used to filter variants for inclusion, based on target capture ROI only and 
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all synonymous base changes were removed. A mutation report containing details of all 
remaining variants (noncoding, missense, nonsense, indels, splice site) was exported for 
further filtering. Variants present in the 1000 Genomes database were removed. Variants 
present in the dbSNP database were removed unless they were assigned a status of 
‘probably-pathogenic’ or ‘pathogenic’ or had a COSMIC ID. Intronic variants up to 8bp from 
splice junctions were assessed for predicted effects on splicing using the SPNN splice site 
prediction tool (http://www.fruitfly.org/seq_tools/splice.html). Only variants with predicted 
effects were retained. The somatic status of post-filtering variants was confirmed by PCR 
and Sanger sequencing of the corresponding matched blood DNA samples as described 
above. 
 
Mutation Analysis of FGFR3, RAS and TP53 
Whole genome amplification (WGA) was performed using the REPLI-g Mini Kit on 25 ng of 
DNA extracted from fresh-frozen tumor samples. WGA amplified DNA samples were used in 
single gene mutation detection assays. SNaPshot assays were used to screen for hotspot 
mutations in FGFR, HRAS, KRAS and NRAS as described previously (Kompier et al., 2010; 
van Oers et al., 2005).  High-resolution melt (HRM) analysis (Taylor, 2009) was used to 
screen for mutations in exons 4-10 of TP53. Primers were designed using Primer3 
(http://frodo.wi.mit.edu/primer3/input.htm) (primer sequences available upon request). Two 
sets of primers were designed to cover exon 4 (4a and 4b). The predicted melting profile of 
the PCR products was determined using DHPLCMelt (http://insertion.stanford.edu/melt.html) 
and in some cases primers were redesigned or had short GC clamps added so that each 
amplicon’s melting temperature was made as simple as possible. PCR for HRM was carried 
out in 10 µl reactions overlaid with 20 µl of mineral oil.  Each reaction contained 1x Acqua 
MasterMix (Acquascience), 1x LCGreen+ (Acquacsience), 4 pmol of each primer, and 2 µl of 
WGA amplified DNA diluted 1/100 with TE.  Cycle parameters were 95°C for 15 min then 45 
cycles of 95°C for 10 s, annealing for 15 s (56-57°C depending on primer pair) and 72°C for 
15 s; after a final denaturation at 94°C for 30 s, reactions were cooled to 25°C at 0.1°C/s to 
promote heteroduplex formation. HRM was carried out using a HR96 LightScanner 
(Acquascience). All samples with melting profiles that differed from WT samples were bi-
directionally sequenced. 
 
Prediction of Effect of Missense Variants 
The web-based Variant Effect Predictor (VEP) tool available through Ensembl was used to 
obtain PolyPhen-2 (Adzhubei et al., 2013) and SIFT (Ng and Henikoff, 2003) pathogenicity 
predictions and scores for the protein products of all missense mutations in the discovery 
and prevalence sets. 
 
Analysis of BRCA2 Mutations 
In silico analysis of BRCA2 variants of uncertain significance was performed with the 
assistance of Alamut Visual 2.7 software (Interactive Biosoftware), and variants were 
classified on a five class system as described by Plon et al. (Plon et al., 2008). Classification 
was based on: the frequency of the variant in normal population datasets (Exome 
Aggregation Consortium (ExAC), Cambridge, MA (URL: http://exac.broadinstitute.org) 
[accessed June 2015]); evidence from the current literature if previously described; in silico 
analysis to predict the impact of missense changes on protein function based on sequence 
conservation [Sorting Intolerant From Tolerant (SIFT) (http://sift.jcvi.org), Align-Grantham 
Variation with Grantham Deviation (A-GVGD) (http://agvgd.iarc.fr), PolyPhen-2 
(genetics.bwh.harvard.edu/pph2)]; and in silico prediction of any effect on splicing using 
splice tools integrated into Alamut Visual. 
 
Gene Ontology Analysis 
Gene ontology analysis was conducted using “Database for Annotation, Visualization and 
Integrated Discovery (DAVID)” v6.7 on a gene list featuring components mutated in two or 
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more patients (261) using whole genome as background. A p value cut off of p < 0.001 and 
a q value (Benjamini) cut off of q<0.05 were implemented. 
 
Mutation Analysis of RHOB 
RHOB was screened for mutations in 36 stage T1 grade 3 samples by direct sequencing. 
Primer sequences are available upon request. 
 
Structural Models of RHOB 
The RHOB-PKN1 model was generated using Modeller based on the coordinates (1cxz) of 
RHOA with two separate HR1a domains (available at PDBePISA).  
 
RHOB Plasmids and Site-Directed Mutagenesis 
Mutant RHOB E32K and E47K expression constructs were generated by site-directed 
mutagenesis of pcDNA3.1(+)-HA-RhoB WT, which contains 3 copies of HA-tag fused to the 
N-terminus of human RHOB. E172K sequence was amplified directly from tumor cDNA. 
Mutants were cloned into KpnI-XbaI-cut pcDNA3.1 by homologous recombination cloning 
(InFusion) according to the manufacturer’s protocol. Primer sequences are available upon 
request. Non-dimerising EGFP (A206K; mEGFP) was amplified from pmEGFP-1 (Addgene) 
and cloned into pcDNA3.1 by InFusion method. WT and mutant RhoB sequences were 
cloned by InFusion method downstream of mEGFP to generate pcDNA-mEGFP-RhoB. All 
inserts and junctions were fully sequenced.  
 
RHOB Functional Studies in HEK293 cells 
For transfection, 2.5 x 106 cells were plated in 10 cm dishes and transfected the following 
day using TransIT-293 with 6.7 μg DNA and 25 μl transfection agent per dish. Rates of 
turnover of WT and mutant forms of RhoB were investigated following cycloheximide (CHX) 
treatment. Twenty-three hr after transfection of HEK293 cells medium was replaced with 
medium containing 100 μg/ml CHX in DMSO. Cells were lysed after 0, 10, 20, 40 and 60 min 
in 200 μl lysis buffer (50 mM Tris-HCl pH7.5, 150 mM NaCl, 10% glycerol, 1% Tween-20, 
0.1% NP-40) containing protease inhibitors and phosphatase inhibitors, debris was pelleted 
and lysates stored at -80°C. 
 
Western Blot Analysis 
Protein (5 ?g) was separated under denaturing conditions in Any kD™ Mini-PROTEAN® 
TGX™ precast polyacrylamide gels (Bio-Rad) and transferred to Amersham Protran 0.45 ?M 
pore size nitrocellulose membrane (GE Healthcare Life Sciences). Blots were incubated with 
primary antibody specific to RHOB in PBS containing 2% skimmed milk powder overnight at 
4?C. Horseradish peroxidase-conjugated secondary antibodies and Luminata Forte Western 
HRP substrate (Millipore) were used for chemiluminescent detection of bound RHOB 
antibody. Blots were reprobed with alpha-tubulin antibody for assessment of protein loading. 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
 
Statistical analysis was done in RStudio for Mac (Version 0.99.486). The statistical test 
LIMMA and a cut off of 0.01 for p value and FDR were applied to identify genes differentially 
expressed between samples belonging to GS1 and GS2. The association between overall 
mutation frequency and each of the two variables gender and smoking status (coded as 
binary: ever smoked yes/no) were assessed using t-tests. For each gene analysed in the full 
set of 82 samples, the association between mutation status and gender were assessed 
using Fisher’s exact test. The significance of association between mutation status and 
recurrence free survival was assessed using log rank test and “survival” package version 
2.39-5. Patients were censored at time of last follow up and events were classified as 
recurrence (>=3 months) post-surgery or death. All p values were adjusted for multiple 
testing using the Benjamini-Hochberg method.  
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DATA AND SOFTWARE AVAILABILITY 
 
All microarray data have been deposited in GEO: GSE93527. 
 
 
Supplemental Tables provided as Excel files 
 
Table S1 related to Figure 1. Details of patients, tumor samples and analyses carried out. 
 
Table S2 related to Figure 2. Genes differentially expressed between tumors belonging to 
subtypes GS1 and GS2. 
 
Table S3 related to Figures 3-6. Variants and APOBEC enrichment values. 
 
 KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Mouse monoclonal anti-CD45 Dako Cat# M0701, RRID: AB_2314143 
Rabbit monoclonal anti-Cyclin B1 Abcam Cat# ab32053, RRID: AB_731779 
Mouse monoclonal anti-FOXA1 Abcam Cat# ab40868, RRID: AB_732410 
Rabbit monoclonal anti-GATA3 Cell Signaling 
Technology 
Cat# 5852S, RRID: AB_10835690 
Rabbit monoclonal anti-Ki67 Thermo Fisher 
Scientific 
Cat# RM-9106-S0, RRID: 
AB_2341197 
Rabbit monoclonal anti-PPARgamma Cell Signaling 
Technology 
Cat# 2435S, RRID: AB_2166051 
Mouse-monoclonal anti-RHOB Santa Cruz Cat# sc-8048, RRID: AB_628219 
Mouse monoclonal anti-STAG2 Santa Cruz Cat# sc-81852, RRID: AB_2199948 
Rat monoclonal anti-alpha-tubulin AbD Serotec Cat# MCA77G, RRID: AB_325003 
Mouse monoclonal anti-Uroplaklin III Abcam Cat# ab78196, RRID: AB_1566851 
Biological Samples 
Fresh-frozen primary bladder tumor 
tissues  
Leeds Multidisciplinary  
Research Tissue Bank 
(University of Leeds) 
http://multirtb.leeds.ac.uk 
Formalin fixed paraffin embedded 
primary bladder tumor tissues 
Leeds Multidisciplinary  
Research Tissue Bank 
(University of Leeds) 
http://multirtb.leeds.ac.uk 
Venous blood samples from bladder 
cancer patients 
Leeds Multidisciplinary  
Research Tissue Bank 
(University of Leeds) 
http://multirtb.leeds.ac.uk 
Chemicals, Peptides, and Recombinant Proteins 
Cycloheximide Sigma Cat# C7698 
Protease inhibitors Sigma Cat# P8340 
Phosphatase inhibitors Sigma Cat# P5726 
Critical Commercial Assays 
Affymetrix GeneChip Human 
Transcriptome Array 2.0  and Genechip 
WT PLUS Reagent Kit  
Affymetrix Cat# 902310 
AmpliTaq Gold DNA Polymerase Thermo Fisher 
Scientific 
Cat# 4311814 
Big Dye Terminator Ready Reaction Mix 
v1.1 Kit 
Thermo Fisher 
Scientific 
Cat# 4336774 
GeneChip Hybridisation, Wash, and 
Stain Kit 
Affymetrix Cat# 900720 
Gentra Puregene Tissue Kit Qiagen Cat# 158667 
HiSeq 2000 Illumina N/A 
illustra Nucleon BACC3 Genomic DNA 
Extraction Kit  
GE Healthcare Cat# RPN8512 
illustra ExoProStar GE Healthcare Cat# US77705  
InFusion HD Cloning Kit Clontech Laboratories Cat# 639650 
NEBNext DNA Library Prep Master Mix 
Set for Illumina 
New England BioLabs Cat# E6040L 
NEBNext Singleplex Oligos for Illumina New England BioLabs Cat# E7350L 
NEBNext High-Fidelity 2X PCR Master 
Mix 
New England BioLabs Cat# M0541L 
Key Resource Table
 PowerPlex 16 System Promega Cat# DC6531 
QIAamp DNA Mini Kit Qiagen Cat# 51306 
REPLI-g Mini Kit Qiagen Cat# 150025 
RNeasy Plus Micro Kit Qiagen Cat# 74034 
SureSelectXT Human All Exon 50Mb Kit Agilent Technologies, 
Inc 
Cat# G3370C 
SureSelectXT Human All Exon v4 Kit Agilent Technologies, 
Inc 
Cat# 5190-4631 
TransIT-293 Mirus Cat# MIR 2700 
Deposited Data 
Raw and processed Affymetrix 
microarray data 
This paper GEO: GSE93527 
A Molecular Taxonomy of Urothelial 
Carcinoma 
Sjödahl et al., 2012 GEO: GSE32894 
Experimental Models: Cell Lines 
Human bladder cancer cell line LUCC8 Derived in this 
laboratory 
N/A 
HEK293 cell line Cancer Research UK, 
London, UK 
N/A 
Recombinant DNA 
pcDNA3.1(+)-HA-RhoB WT cDNA Resource 
Center, Bloomsburg 
University  
Clone ID: RHO0B0tN00 
pmEGFP-1 Gift from Benjamin 
Glick 
Addgene Cat# 36409 
Software and Algorithms 
Affymetrix Expression Console Software Affymetrix http://www.Affymetrix.com/ 
BWA Li and Durbin, 2009 https://sourceforge.net/projects/bio-
bwa/ 
ConsensusClusterPlus (CCP) Wilkerson and Hayes, 
2010 
http://bioconductor.org/packages/Co
nsensusClusterPlus/ 
Cytoscape Shannon et al., 2003 www.cytoscape.org/ 
DAVID Dennis et al., 2003 https://david.ncifcrf.gov/ 
EnrichmentMap Merico et al., 2010 http://baderlab.org/Software/Enrich
mentMap 
GATK Broad Institute https://broadinstitute.org/gatk/ 
Genome MuSic Package Dees et al., 2012     http://gmt.genome.wustl.edu/packag
es/genome-music/ 
GSEA Subramanian et al., 
2005 
http://software.broadinstitute.org/gs
ea/ 
Modeller Eswar et al., 2006 https://salilab.org/modeller/ 
Nexus Copy Number Biodiscovery, Inc http://www.biodiscovery.com/nexus-
copy-number/ 
ngCGH Gartner et al., 2012 https://github.com/seandavi/ngCGH 
PDBePISA European 
Bioinformatics Institute 
www.ebi.ac.uk/pdbe/pisa/ 
Picard Broad Institute https://broadinstitute.github.io/picard
/ 
R2: Genomics Analysis and 
Visualization Platform 
Jan Koster, Academic 
Medical Center, 
Netherlands 
http://r2.amc.nl/ 
 R-Studio for Mac R-Studio https://www.rstudio.com/products/rs
tudio/download/ 
SAMtools Li et al., 2009 http://samtools.sourceforge.net 
Variant Effect Predictor (VEP) Ensembl http://www.ensembl.org/Homo_sapi
ens/Tools/VEP 
VarScan2 Koboldt et al., 2012 http://dkoboldt.github.io/varscan  
 
 
Figure Click here to download Figure Figure 1 revised 25_7_17.tif 
Figure Click here to download Figure Figure 2 revised 25_7_17.tif 
Figure Click here to download Figure Figure 3 revised 25_7_17.tif 
Figure Click here to download Figure Figure 4 revised25_7_17.tif 
Figure Click here to download Figure Figure 5 revised 25_7_17.tif 
Figure Click here to download Figure Figure 6 revised 25_7_17.tif 
Table S1 related to Figure 1. Details of patients, tumor samples and analyses carried out.  
Provided as an Excel File.  
  
 
Table S2 related to Figure 2. Genes differentially expressed between tumors belonging to 
subtypes GS1 and GS2. 
Provided as an Excel File.   
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Figure S1 related to Figure 2.  Alignment of GS1 and GS2 expression profiles with previously 
identified NMIBC expression subtypes. 
(A) Tabular representation of tumor sample membership assignments based on; hierarchical clustering of 
copy number data (Genomic Subtype), nearest neighbour analysis results using Lund n=308 dataset as 
training set, or consensus clustering of microarray data after application of UROMOL classifier.  
(B) UROMOL 117 gene classifier was applied to microarray data from Ta tumors (n=79), results are 
represented as consensus cluster plot (k=3).  
(C) Heatmap representation of gene z-scores associated with late cell cycle and DNA repair (Bonferroni 
adjusted p value < 0.01). 
(D) Boxplot representation of KI67 index (percentage of positive cells) according to GS1 and GS2 
subtype membership. Each box has lines at the lower quartile, median quartile and upper quartile values. 
Whiskers represent the minimum and maximum values.  
 
 
Figure S2, related to Figure 2. Immunohistochemistry for selected proteins in tumors from GS1 
and GS2 subtypes. 
 
(A-B) Expression of KI67, CCNB1, GATA3, FOXA1, PPARG and UPKIII in GS1 (A) and GS2 (B) subtype 
tumors. Scale bars: 50µm. 
 
 
 
 
 
 
Table S3 related to Figures 3-6. Variants and APOBEC enrichment values. 
Provided as an Excel File.   
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure S3, related to Figure 3. Distribution of mutation type and nucleotide substitutions in stage 
Ta bladder cancer exome sequences. 
 
(A) Frequency and type of mutations in 23 stage Ta tumors and a cell line (LUCC8, patient 1838).  Loss 
of function (LOF) mutations comprise nonsense, frameshift and splicing mutations. Shown below are 
information on gender (red, female; blue, male), smoking status (black, ever-smoker; grey, never-smoker) 
and genomic subtype (green, GS1; blue, GS2).  
(B) Nucleotide substitutions identified in bladder cancer exome sequences.  
(C) Values characterizing APOBEC mutagenesis in the individual samples (all underlying vaues are in 
Table S3 sheet S3C). 
a. Fold enrichment of the APOBEC mutagenesis signature over the expected occurrence for random 
mutagenesis in individual samples. Fold enrichment values are taken from the “APOBEC enrichment” 
column. 
b. Relative load of APOBEC signature mutations. The Fraction of Total Mutations values were taken from 
the “APOBEC fraction of total mutations” column.  
c. Minimum estimate of the number of APOBEC induced mutations in a sample. “APOBEC Mutation Load 
(minimum estimate)” is calculated only for samples passing 0.05 FDR threshold for APOBEC enrichment 
[”BH_Fisher_p-value_tCw”] =<0.05. Samples with “BH_Fisher_p-value_tCw” value greater than 0.05 
receive a value of 0. “APOBEC_MutLoad_MinEstimate” is plotted on a logarithmic scale (with a 
pseudocount of 1) for better visualization of values in all sections of its range.  
(D) APOBEC mutagenesis is the strongest source of mutations in NIBC.  
Y- axis shows the log10-transformed total numbers or numbers of categories of mutations in a sample. X-
axis shows log10-transformed (with a pseudo count of +0.1 to allow plotting of zero values) values of the 
“APOBEC Mutation Load (minimum estimate)”. 
  
Gene Chromosome Indels SNVs Total	Mutations Covd	Bps Muts	pMbp p	value	FCPT p	value	LRT p	value	CT FDR	FCPT FDR	LRT FDR	CT
Genes	with	significant		mutation	frequency	from	Genome	MuSic	analysis
PIK3CA 3 0 16 16 87670 182.5 0 0 0 0 0 0
FGFR3 4 0 11 11 64279 171.13 1.64E-13 0 9.77E-19 1.27E-09 0 7.56E-15
KDM6A X 5 5 10 225332 44.38 7.21E-10 8.43E-14 4.46E-14 4.18E-06 4.89E-10 2.59E-10
STAG2 X 3 4 7 129461 54.07 1.70E-07 2.77E-09 1.90E-11 0.00078693 1.07E-05 7.34E-08
HRAS 11 1 5 6 44463 134.94 2.40E-07 3.84E-09 1.89E-11 0.0009282 1.13E-05 7.34E-08
EP300 22 1 7 8 176308 45.38 2.92E-05 1.47E-06 3.19E-08 0.09682411 0.0028175 9.26E-05
RHOB 2 0 3 3 14241 210.66 0.00349597 8.80E-07 1.53E-06 1 0.00185793 0.0029518
ARID1A 1 3 1 4 269952 14.82 0.00740156 1.70E-06 3.19E-05 1 0.0028175 0.04627192
Genes	selected	for	SureSelect	capture
ARHGAP18 6
ARID1A* 1
ARID4A* 14
ASH1L* 1
ATP6V1B2 8
ATP7B 13
BRCA2* 13
CEP290 12
CLTC 17
CLU 8
COL11A1 1
CREBBP* 16
DLG4 17
DOPEY1 6
DYNC1H1 14
EP300* 22
HEPACAM 11
HERC1 15
ITK 5
KDM3A* 2
KDM6A* X
KIF16B 20
LARP1B 4
MAGI3 1
MECOM* 3
KMT2A* 11
KMT2D* 12
KMT2C* 7
NAT10 11
NCOR1* 17
PALM3 19
PGS1 17
PHF3 6
PIK3CA 3
RAB11FIP1 8
RAD21* 8
RBM10 X
RBM6 3
RHOB 2
RREB1 6
STAG2* X
STK38* 6
TET3 2
TSC1 9
UEVLD 11
UNC80 2
USP47 11
UTY* Y
ZFYVE26 14
Muts	pMbp The	total	number	of	mutations	per	Mb	=	(Total	Mutations	/	Covd	Bps)	*	1e6
p	value	FCPT p	value	for	significance	of	the	gene	using	the	Fisher's	Combined	P	value	test
p	value	LRT p	value	for	significance	of	the	gene	using	the	Likelihood	Ratio	test
p	value	CT p	value	for	significance	of	the	gene	using	the	Convolution	test
FDR	FCPT FDR	for	significance	of	the	gene	using	the	Fisher's	Combined	P-value	test
FDR	LRT FDR	for	significance	of	the	gene	using	the	Likelihood	Ratio	test
FDR	CT FDR	for	significance	of	the	gene	using	the	Convolution	test
*	Genes	with	CM	function	from	DAnCER	database;	http://wodaklab.org/dancer/
Table	S4	related	to	Figure	3.	Significantly	mutated	genes	identified	by	Genome	MuSic	analysis	of	exome	sequence	data	and	genes	selected	for	targeted	sequencing		
 
 
 
 
 
Figure S4, related to Figure 3. Schematics showing the distribution of mutations identified by 
exome sequencing and targeted re-sequencing in 82 stage Ta bladder tumors. 
 
(A) Mutations in KMT2D, KMT2C, CREBBP, EP300, STAG2 and ARID1A proteins (top bars). Lower bars 
show cDNA sequence with positions of splice site mutations. 
(B) Missense mutations in PIK3CA. ABD, adapter binding domain; RBD, Ras-binding domain; C2, C2 
PI3K class I alpha. 
 
 
 
 
Figure S5, related to Figure 3. Mutual exclusivity and co-occurrence of mutations in stage Ta 
tumors. 
  
(A) The upper right triangle (red) represents mutually exclusive relationships and lower left triangle (blue) 
represents co-occurrent relationships between 52 genes with somatic mutations in 82 stage Ta tumors. p 
value and FDRs were calculated using the Fisher’s exact test and heatmap values reflect -log10 (p 
value). p values (-log10) greater than 3 were assigned the maximum score. 
(B) Co-occurrence and mutual exclusivity correlations. Listed are results of Fisher’s exact tests for 
significantly mutated genes to a maximum p value of 0.05.  False discovery rate (FDR) is also reported. 
 
 
Ensembl gene ID Genomic position (hg19)
Variant 
type Variant effect Ensembl transcript ID cDNA change Protein change SIFT(score) PolyPhen(score)
Variant 
class*
Sample/ 
patient ID
Somatic/ 
germline MAF§
ENSG00000139618 13:32912678 C>G SNV Missense ENST00000544455 c.4186 C>G p.Q1396E tolerated(1) benign(0) Class 2 718 Somatic 47
ENSG00000139618 13:32912846 C>T SNV Nonsense ENST00000544455 c.4354 C>T p.Q1452* - - Class 5 718 Somatic 47
ENSG00000139618 13:32906732 C>T SNV Nonsense ENST00000544455 c.1117 C>T p.Q373* - - Class 5 1116 Somatic 21
ENSG00000139618 13:32899251 A>G SNV Missense ENST00000544455 c.355 A>G p.T119A tolerated(0.11) possibly damaging(0.469) Class 2 1117 Somatic 50
ENSG00000139618 13:32893393 G>C SNV Missense ENST00000544455 c.247 G>C p.E83Q deleterious(0.01) benign(0.246) Class 3 1307 Somatic 46
ENSG00000139618 13:32911598 G>C SNV Missense ENST00000544455 c.3106 G>C p.E1036Q tolerated(0.1) probably damaging(0.943) Class 3 1474 Somatic 48
ENSG00000139618 13:32912318 G>C SNV Missense ENST00000544455 c.3826 G>C p.E1276Q tolerated(0.09) probably damaging(0.953) Class 2 1527 Somatic 46
ENSG00000139618 13:32969035 C>G SNV Missense ENST00000544455 c.9466 C>G p.Q3156E deleterious(0) benign(0.303) Class 3 1527 Somatic 45
ENSG00000139618 13:32910799_32910804 del6 Deletion In-frame deletion ENST00000544455 c.2307_2312 del6 p.I770_L771del - - Class 3 1991 Somatic 62
ENSG00000139618 13:32936728 G>C SNV Missense ENST00000544455 c.7874 G>C p.R2625T deleterious(0) probably damaging(0.993) Class 3 2013 Somatic 34
ENSG00000139618 13:32911181 G/C SNV Missense ENST00000544455 c.2689 G/C p.E897Q deleterious(0.04) possibly_damaging(0.508) Class 3 712 Germline N/A
ENSG00000139618 13:32915315 G/A SNV Missense ENST00000544455 c.6823 G/A p.E2275K tolerated(0.46) benign(0.217) Class 3 1231 Germline N/A
ENSG00000139618 13:32929284 A/G SNV Missense ENST00000544455 c.7294 A/G p.R2432G deleterious(0) benign(0.001) Class 2 575 Germline N/A
ENSG00000139618 13:32937324 C/A SNV Missense ENST00000544455 c.7985 C/A p.T2662K deleterious(0) benign(0.003) Class 3 712 Germline N/A
ENSG00000139618 13:32972626 A/T SNV Nonsense ENST00000544455 c.9976 A/T K3326* - - 1474 Germline N/A
* Classification according to Association for Clinical Genetic Science (ACGS) Guidelines
2  Unlikely to be pathogenic
3  Unknown significance
5  Clearly pathogenic
§ Mutant allele frequency
Table S5 related to Figure 3. BRCA2  somatic and germline variants
  
 
 
 
 
Figure S6, related to Figure 3. Comparison of mutations identified in NIBC and MIBC. 
 
Frequencies of mutations identified by exome and targeted sequencing of 82 stage Ta tumors in this 
study and data from 130 muscle-invasive bladder tumors analysed by The Cancer Genome Atlas 
Research Network [Data accessed from cBioPortal (http://cbioportal.org/public-portal/index.do)] are 
shown.
Gene*
Total 
mutations
Inactivating 
mutations
ACTB 1 0
ACTR6 1 0
ADAR 1 0
APPL1 1 0
ARID1A 4 3
ARID2 2 2
ARID4A 1 1
ASH1L 2 2
ATRX 1 0
AURKB 1 1
BANF1 1 0
BAZ1A 1 0
BAZ2A 1 1
BRCA1 1 0
BRCA2 3 0
CARM1 1 0
CENPK 1 0
CHEK1 1 0
CHEK2 1 0
CREBBP 5 3
DHX30 1 0
DHX9 1 0
EMD 1 0
EP300 9 7
EPC2 1 0
GSG2 2 0
HDAC6 1 0
HDAC9 1 0
HELLS 1 0
HESX1 1 0
HEY2 1 1
HIRA 1 0
HNRNPR 1 0
HSP90AA1 2 0
HSPA8 1 1
HUWE1 2 0
INO80 1 0
JMJD1C 1 0
KDM3A 1 1
KDM6A 11 10
KIF11 1 0
KIF4A 1 0
LEO1 1 0
MECOM 2 2
MGA 1 0
KMT2A 4 2
KMT2D 7 4
KMT2C 3 2
MTA1 1 0
MYSM1 2 0
Table S6 related to Figure 3. Chromatin 
modification genes with mutation in 24 
bladder tumor exomes
NASP 5 0
NCOA3 1 0
NCOR1 1 1
NCOR2 1 0
NOC2L 1 0
NPM1 1 0
PABPC1 3 0
PHC3 1 0
PHF17 1 0
POLR2A 1 0
PRDM2 1 0
RAD21 1 1
RREB1 2 1
RSF1 1 0
SETD1A 1 0
SIRT4 1 0
SMC3 1 1
SND1 2 0
SP1 1 0
SRCAP 1 0
STAG2 9 7
STK38 1 1
SUPT6H 2 0
SUV420H1 1 1
SYCP3 1 0
TACC2 1 0
TAF1 1 0
TAF5L 1 0
TBL1XR1 3 1
TLE2 1 0
TOP2B 2 0
UTY 4 2
WHSC1L1 2 0
ZEB1 2 0
* Genes with CM function from DAnCER database; http://wodaklab.org/dancer/
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